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dinitrochloro benzene have been used 
for melanoma therapy in both preclini-
cal and clinical studies (Terheyden et 
al., 2007; Wack et al., 2002). However, 
as elegantly demonstrated by van 
den Boorn et al. (2011, this issue), 
mono benzone is more specific than 
dinitrochlorobenzene because it is active 
only in pigmented cells. Moreover, it is 
already available as a registered drug 
with a well-established toxicity profile. 
It is hoped the present report by van den 
Boorn et al. will prompt clinical trials 
testing this concept for immunotherapy 
of melanoma.
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Fisetin: A natural Fist  
against Melanoma?
Jack L. Arbiser1 and David E. Fisher2
Melanoma has now become the subject of targeted therapies, based upon the 
high prevalence of B-raf mutations in melanoma. However, while initial responses 
to B-raf inhibitors are impressive, resistance is extremely common, suggesting that 
melanoma is not addicted to B-raf. In their report, Syed et al. demonstrate that 
fisetin, a natural product without well established mechanisms, has activity against 
melanoma. Their report suggests that "nontargeted therapies" need to become 
part of our armamentarium against melanoma, given that targeted therapies do 
not target all of the pathways required for melanoma growth.
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Several common genetic events in 
melanoma have been elucidated in 
recent years. These include onco-
genic events, such as the B-raf V600E 
mutation, amplification of the micro-
phthalmia transcription factor (MITF), 
and Nras mutations. Common tumor 
suppressor events include inactivation 
of the p16ink4a tumor suppressor gene, 
often by deletion or hyper methylation, 
and loss and/or mutation of PTEN, a 
common event in melanomas with 
B-raf mutations. Melanomas have 
been shown to exhibit differing genetic 
pathways to reach these mutations, 
depending on their anatomic location. 
The pathways involve a complex inter-
play among pigmentation genes such 
as melanocortin 1 receptor, c-kit, and 
DNA repair genes.
As our understanding of melano-
ma genetics has increased, so has our 
understanding of the signaling pathways 
relevant to melanoma progression. The 
current concept of atypical nevi giving 
rise to a non invasive melanoma (radial 
growth phase) and then to an invasive 
and potentially metastatic phenotype 
has been confirmed with distinct sig-
naling events, although melanomas 
may also arise in the absence of pre-
existing nevi. Atypical nevi are clonal 
neoplasms with a high frequency of 
B-raf mutations, but despite the activa-
tion of B-raf, they do not exhibit stable 
activation of MAP kinase (p42/44 ERK). 
Radial growth melanoma demonstrates 
high levels of expression of acti-
vated MAP kinase, as well as of Id-1 
and telomerase. Invasive melanoma 
autophagy. J Invest Dermatol 131:1240–51
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demonstrates high levels of Akt activa-
tion, through either loss of PTEN (thus 
causing Akt1 activation) or amplifica-
tion of Akt3. Akt activation has been 
shown to be transforming for human 
melanoma, resulting in the activation of 
reactive oxygen. Indeed, the phenotype 
of loss of p16ink4a, Akt activation, and 
reactive oxygen generation has been 
termed the “reactive oxygen–driven 
tumor,” and reactive oxygen is prob-
ably a major source of NF-kB activation 
through oxidative inactivation of IkB.
Although the genetics and signal-
ing of melanoma are increasingly well 
understood, directing treatment against 
these events has lagged. The discovery of 
B-raf mutations led to clinical testing of a 
first-generation B-raf inhibitor, sorafenib. 
Although relatively potent, sorafenib 
lacks selectivity, and its clinical activity 
against melanoma in humans was dis-
appointing. Nevertheless, this lack of 
specificity turned out to be beneficial 
because sorafenib is a potent inhibitor 
of VEGFR2 and is therefore used to treat 
the highly angiogenic neoplasm renal 
cell carcinoma. More selective mutant-
specific B-raf inhibitors have been devel-
oped, including PLX4720, and these 
have entered clinical trials. PLX4032 has 
resulted in remission of advanced mela-
nomas in ~80% of patients, but not in 
cures (Flaherty et al., 2010).
Single-agent targeted therapies 
have only rarely (if ever) cured patients 
with cancer. The clinical efficacy of 
B-raf(V600E) selective antagonists has 
met with great enthusiasm in recent 
months. Yet the precise mechanism of 
killing remains uncertain, and the magni-
tude of clinical responses seems to be less 
than might have been predicted, despite 
strong suppression of B-raf(V600E). 
Moreover, the failure of B-raf inhibi-
tion alone to produce more substantial 
responses or cure suggests that other 
lesions/pathways within melanomas play 
roles in controlling tumorigenic behav-
ior. Indeed, PLX4032-resistant mela-
nomas arise all too readily, displaying 
a variety of mechanisms of resistance, 
including Nras mutations, Craf overex-
pression, COT amplification, and activa-
tion of other tyrosine kinase receptors. 
This suggests that B-raf-independent 
pathways are also likely to play impor-
tant roles in melanoma—roles that may 
require broader therapeutic approaches.
In this issue, Syed et al. demonstrate 
antimelanoma activity of fisetin, a tet-
rahydroxyflavone that is found in the 
Rhus family (including mangoes and 
other plants). Flavones are a family of 
compounds composed of polyphenols, 
which include other biologically active 
compounds, such as curcuminoids, 
epicatechins, resveratrols, and honoki-
ols. Syed et al. have demonstrated that 
fisetin exhibits several activities that are 
potentially beneficial in treating mela-
noma. These include downregulation 
of nuclear b-catenin with concomitant 
downregulation of Wnt signaling path-
ways, resulting in suppression of MITF, 
an amplified oncogene in ~20% of 
metastatic melanomas. Fisetin-induced 
MITF suppression was found to be 
dependent on glycogen synthase kinase 
activity. Importantly, fisetin was active in 
xenograft models of melanoma at doses 
of 45 mg/kg.
Despite the extensive studies of poly-
phenols, this vast group of compounds is 
underrepresented in clinical medicine. 
The only polyphenol-based drug current-
ly used is Veregen (15% polyphenon E), 
for the treatment of external genital warts. 
Lack of enthusiasm for the development 
of polyphenol-based drugs appears to 
be widespread among drug companies 
and academic institutes as well as in 
the National Institutes of Health–based 
Developmental Therapeutic Program.
The most active decade in neoplas-
tic drug development was 1960–1970. 
During this time, most of the currently 
available antineoplastic agents were syn-
thesized, especially antimetabolites and 
alkylating agents. Investigators knew lit-
tle of the mechanisms of actions of drugs, 
they had not yet sequenced any genom-
es, and they performed less sophisticated 
assays. A few cell lines were used, and 
if a compound showed activity in vivo, 
animal testing was performed, often on 
the rapidly growing L1210 leukemia 
cell line. They did not know whether the 
observed activities were due to apopto-
sis, autophagy, mitotic catastrophe, or 
cell cycle arrest. Promising animal data 
were followed by clinical trials. Drugs 
that are still useful today—e.g., metho-
trexate, 5-fluorouracil, cisplatin, and 
vinca alkaloids—were all developed in 
this way. Efficacy was the main concern, 
and mechanisms were studied later.
By contrast, the decade 2000–2010 
witnessed an explosion of new informa-
tion. Investigators sequenced numerous 
genomes, including the human genome. 
One can take a portion of a human mela-
noma specimen from a patient and find 
not only B-raf or Nras mutations but also 
amplifications and mutations in multiple 
tyrosine kinases in a single specimen. 
Potent inhibitors of each of the tyrosine 
kinases, for example, as has been done 
with B-raf and EGFR, may be taken to the 
clinic. This more sophisticated approach 
has brought significant clinical benefit to 
small groups of cancer patients, although 
cure remains rare. Many investigators have 
been profoundly energized by this prog-
ress because it is mechanism based and 
therefore highly predictive. It also permits 
a significantly more focused approach to 
understanding mechanisms of resistance 
to such targeted small molecules. Yet, 
despite the elegance of this approach, 
the ultimate significance of these inhibi-
tors has lagged behind some of the 
older standbys: methotrexate, Cytoxan, 
and cisplatin. An important question is 
whether investigators are accomplishing 
less but with more resources.
Clinical Implications
•  Forty years ago, novel and effective therapeutic agents were derived 
most often from biologically active natural products, usually without 
knowledge of mechanisms.
•  More recently, new information about regulatory aspects of the human 
genome have led to the development of “signaling-specific” agents for 
cancer, but only some of them have proven useful.
•  Syed et al. now demonstrate antimelanoma activity of fisetin, a 
tetrahydroxyflavone found in the Rhus family (including mangoes), 
suggesting that the older methods may retain significant merit.
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Two reports in this issue of the Journal 
of Investigative Dermatology shed light 
on possible mechanisms of action of 
fumarate esters. Meissner et al. (2011) 
demonstrate that dimethylfumarate 
causes a decrease in tube formation 
in human endothelial cells in vitro. 
Analysis of angiogenic factors in 
endothelial cells treated with dimethyl-
fumarate revealed a decrease in vascu-
lar endothelial growth factor receptor 
2 (VEGFR2) protein but not in VEGFR1 
or neuropilin-1. Because VEGFR2 tran-
scription is dependent on the Sp1 tran-
scription factor, the researchers ana-
lyzed the effect of dimethylfumarate 
and demonstrated decreased binding 
of the Sp1 transcription factor to the 
VEGFR2 promoter. García-Caballero 
et al. (2011) also demonstrated inhi-
bition of tube formation on Matrigel 
by dimethylfumarate, but not by 
mono methylfumarate or free fumaric 
acid itself. They found that dimethyl-
fumarate does not inhibit the kinase 
activity of VEGFR2, and they demon-
strated antiangiogenic activity in two in 
vivo models: the quail chorioallantoic 
membrane and a transgenic zebrafish 
in which the endothelial cells are 
labeled with green fluorescent protein. 
Thus, it is safe to say that angiogenesis 
inhibition probably plays a role in the 
activity of dimethylfumarate.
One component to this question 
involves the decreased use of natural 
products as drugs or drug leads. The 
movement away from natural products 
probably reflects the complex synthet-
ic chemistry and medicinal chemistry 
requirements to optimize delivery and 
oral bioavailability and to minimize 
toxicity. Yet natural products tend to 
produce significant biological activ-
ity, presumably because nature has 
evolved three-dimensional configura-
tions that fit the “grooves and turns” of 
biochemically important molecules. 
In addition, many natural products 
are likely to target multiple species, 
thereby making the elucidation of their 
mechanism of action more challenging 
to dissect.
Although it is difficult to fully define 
mechanism, we know it when we see 
it. Mechanism is often presented as a 
crystal structure of a compound nestled 
in the crevices of a mutant protein, 
with hydrogen bonds of the target com-
pound closely approximating critical 
catalytic residues in the target protein. 
Polyphenols do not fit this conception 
of mechanism, because in most cases, 
including that of fisetin, we don’t even 
know the target protein. In fact, we don’t 
know whether it is a single target protein 
or multiple target proteins or whether 
the compounds inhibit protein–protein 
interactions. We do know that the com-
pound has downstream signaling activi-
ties that are important, such as upregu-
lation of E-cadherin and downregulation 
of c-myc and N-cadherin. Thus, efficacy 
in the absence of knowledge of precon-
ceived mechanism makes investigators 
uncomfortable, because it diminishes 
predictability. Apparently the same may 
be true of regulatory agencies, such as 
the Food and Drug Administration in 
the United States.
Better treatments for melanoma are 
possible, and they may be right around 
the corner. Perhaps a rejuvenated inter-
est in natural products would provide 
a boost—especially if combined with 
modern methods of target identification, 
pathway analysis, biomarker discovery, 
and combinatorial treatments. The 
power of nature’s tools is remarkable. 
Investigators understood this 40 years 
ago; revisiting the concept more vigor-
ously might benefit patients.
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Fumarate esters as Angiogenesis 
Inhibitors: Key to Action in Psoriasis?
Jack L. Arbiser1,2,3
Fumarate esters—an oral therapy for psoriasis—are used primarily in europe, 
but not at all in the United States. Given that biological therapies are exceed-
ingly expensive and pose an increased risk for infections and malignancy, 
the need for safer and less expensive therapies for psoriasis is compelling. 
nonbiological therapies for psoriasis, including methotrexate and system-
ic retinoids, carry potentially severe side effects and relatively high cost. 
Fumarate, a natural product that is generated internally in humans during 
the Krebs cycle, is an attractive alternative to these therapies. However, the 
mechanism for fumarate’s activity in psoriasis remains unknown.
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